Table 2.

Multivariable analyses for overall survival, progression-free survival, objective response rate, and disease control rate in the propensity score matched (PSM) sample.

Variables	OS HR (95% CI)	PFS HR (95% CI)	ORR OR (95% CI)	DCR OR (95% CI)
Vaccine	p = 0.005	p = 0.062	p = 0.08	p = 0.007
No	1.00	1.00	1.00	1.00
Yes	0.75 (0.62–0.92)	0.85 (0.72–1.01)	1.27 (0.97–1.67)	1.47 (1.11–1.96)
Sex	p = 0.46	p = 0.84	p = 0.92	p = 0.68
M	1.09 (0.87–1.36)	1.02 (0.85–1.23)	0.98 (0.72–1.34)	1.07 (0.78–1.47)
F	1.00	1.00	1.00	1.00
Age (in years)	1.0 (0.99–1.01) p = 0.53	1.00 (0.99–1.01) p = 0.50	1.0 (0.99–1.02) p = 0.66	1.01 (0.99–1.02) p = 0.24
ECOG PS	p < 0.0001	p < 0.0001	p = 0.025	p = 0.004
0	1.00	1.00	1.00	1.00
1–2	1.87 (1.53–2.29)	1.59 (1.34–1.88)	0.72 (0.55–0.96)	0.65 (0.49–0.87)
Smoking habits	p = 0.12	p = 0.16	p = 0.38	p = 0.28
Never	1.00	1.00	1.00	1.00
Former	0.76 (0.58–0.99)	0.82 (0.66–1.03)	1.24 (0.87–1.77)	1.35 (0.93–1.96)
Current	0.84 (0.63–1.12)	0.81 (0.63–1.04)	1.03 (0.68–1.54)	1.22 (0.81–1.84)
Tumour site	p < 0.0001	p = 0.001	p = 0.66	p = 0.31
Lung	1.62 (1.03–2.55)	1.54 (1.06–2.24)	0.67 (0.38–1.15)	0.59 (0.31–1.12)
RCC	0.97 (0.59–1.60)	1.31 (0.88–1.96)	0.65 (0.35–1.19)	0.75 (0.37–1.50)
Melanoma	0.85 (0.50–1.46)	0.80 (0.51–1.26)	0.84 (0.45–1.59)	0.79 (0.38–1.64)
UC	1.69 (0.94–3.04)	1.57 (0.96–2.57)	0.80 (0.38–1.70)	0.48 (0.21–1.10)
H&N	2.61 (1.38–4.91)	1.95 (1.12–3.38)	0.71 (0.28–1.79)	0.42 (0.16–1.11)
Others	1.00	1.00	1.00	1.00
Comorbidities	p = 0.73	p = 0.26	p = 0.41	p = 0.84
No	1.00	1.00	1.00	1.00
Yes	1.04 (0.82–1.34)	1.13 (0.92–1.39)	1.15 (0.83–1.61)	0.97 (0.68–1.36)

OS = overall survival; PFS = progression-free survival; ORR = objective response rate; DCR = disease control rate; HR = hazard ratio; OR = odds ratio; ECOG PS = European Cooperative Oncology Group performance status; RCC = renal cell carcinoma; UC = urothelial cancer; H&N = head and neck.